Zobrazit v EDS

Biomarkers for the Early Detection of Pancreatic Ductal Adenocarcinoma

Uloženo v:
Podrobná bibliografie
Název: Biomarkers for the Early Detection of Pancreatic Ductal Adenocarcinoma
Autoři: Borrebaeck, Carl A.K., Mellby, Linda D., King, Thomas C.
Přispěvatelé: Lund University, Faculty of Engineering, LTH, Departments at LTH, Department of Immunotechnology, Lunds universitet, Lunds Tekniska Högskola, Institutioner vid LTH, Institutionen för immunteknologi, Originator, Lund University, Faculty of Engineering, LTH, Other operations, LTH, Create Health, Lunds universitet, Lunds Tekniska Högskola, Annan verksamhet, LTH, Create Health, Originator, Lund University, Profile areas and other strong research environments, Other Strong Research Environments, LUCC: Lund University Cancer Centre, Lunds universitet, Profilområden och andra starka forskningsmiljöer, Övriga starka forskningsmiljöer, LUCC: Lunds universitets cancercentrum, Originator, Lund University, Faculty of Engineering, LTH, LTH Profile areas, LTH Profile Area: Engineering Health, Lunds universitet, Lunds Tekniska Högskola, LTH profilområden, LTH profilområde: Teknik för hälsa, Originator
Zdroj: Gastrointestinal Cancers. :85-100
Témata: Medical and Health Sciences, Clinical Medicine, Cancer and Oncology, Medicin och hälsovetenskap, Klinisk medicin, Cancer och onkologi
Popis: Pancreatic ductal adenocarcinoma has one of the worst survival rates among adult cancers, with only 11% in the United States surviving five years after diagnosis. The majority of patients are diagnosed with late-stage disease, since early-stage pancreatic ductal adenocarcinoma is typically either asymptomatic or presents with non-specific symptoms. Pancreatic ductal adenocarcinoma thus remains a highly fatal disease. Today, surgical resection (removal of the pancreas) is the only potentially curative modality of treatment available. Detecting pancreatic cancer lesions early enough to perform surgery is, however, beset with difficulties. Nevertheless, the timeline of progression from low-grade precursor lesions to invasive cancer does offer a window of opportunity to detect the disease earlier than is currently possible. By providing physicians with actionable information early enough for the cancer to be removed surgically, the overall 5-year pancreatic ductal adenocarcinoma survival rate could increase from 11% to over 50%. In this chapter, we describe the development and clinical implementation of a proteomic, multi-biomarker blood test for the early detection of pancreatic ductal adenocarcinoma.
Přístupová URL adresa: https://doi.org/10.36255/exon-publications-gastrointestinal-cancers-biomarkers-pancreatic-cancer
Databáze: SwePub
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://doi.org/10.36255/exon-publications-gastrointestinal-cancers-biomarkers-pancreatic-cancer#
    Name: EDS - SwePub (s4221598)
    Category: fullText
    Text: View record in SwePub
  – Url: https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=EBSCO&SrcAuth=EBSCO&DestApp=WOS&ServiceName=TransferToWoS&DestLinkType=GeneralSearchSummary&Func=Links&author=Borrebaeck%20CAK
    Name: ISI
    Category: fullText
    Text: Nájsť tento článok vo Web of Science
    Icon: https://imagesrvr.epnet.com/ls/20docs.gif
    MouseOverText: Nájsť tento článok vo Web of Science
Header DbId: edsswe
DbLabel: SwePub
An: edsswe.oai.portal.research.lu.se.publications.6b0a57a7.eb00.45a9.ab59.717692b71cc8
RelevancyScore: 1130
AccessLevel: 6
PubType: Book
PubTypeId: book
PreciseRelevancyScore: 1129.736328125
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Biomarkers for the Early Detection of Pancreatic Ductal Adenocarcinoma
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Borrebaeck%2C+Carl+A%2EK%2E%22">Borrebaeck, Carl A.K.</searchLink><br /><searchLink fieldCode="AR" term="%22Mellby%2C+Linda+D%2E%22">Mellby, Linda D.</searchLink><br /><searchLink fieldCode="AR" term="%22King%2C+Thomas+C%2E%22">King, Thomas C.</searchLink>
– Name: Author
  Label: Contributors
  Group: Au
  Data: Lund University, Faculty of Engineering, LTH, Departments at LTH, Department of Immunotechnology, Lunds universitet, Lunds Tekniska Högskola, Institutioner vid LTH, Institutionen för immunteknologi, Originator<br />Lund University, Faculty of Engineering, LTH, Other operations, LTH, Create Health, Lunds universitet, Lunds Tekniska Högskola, Annan verksamhet, LTH, Create Health, Originator<br />Lund University, Profile areas and other strong research environments, Other Strong Research Environments, LUCC: Lund University Cancer Centre, Lunds universitet, Profilområden och andra starka forskningsmiljöer, Övriga starka forskningsmiljöer, LUCC: Lunds universitets cancercentrum, Originator<br />Lund University, Faculty of Engineering, LTH, LTH Profile areas, LTH Profile Area: Engineering Health, Lunds universitet, Lunds Tekniska Högskola, LTH profilområden, LTH profilområde: Teknik för hälsa, Originator
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <i>Gastrointestinal Cancers</i>. :85-100
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Medical+and+Health+Sciences%22">Medical and Health Sciences</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+Medicine%22">Clinical Medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer+and+Oncology%22">Cancer and Oncology</searchLink><br /><searchLink fieldCode="DE" term="%22Medicin+och+hälsovetenskap%22">Medicin och hälsovetenskap</searchLink><br /><searchLink fieldCode="DE" term="%22Klinisk+medicin%22">Klinisk medicin</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer+och+onkologi%22">Cancer och onkologi</searchLink>
– Name: Abstract
  Label: Description
  Group: Ab
  Data: Pancreatic ductal adenocarcinoma has one of the worst survival rates among adult cancers, with only 11% in the United States surviving five years after diagnosis. The majority of patients are diagnosed with late-stage disease, since early-stage pancreatic ductal adenocarcinoma is typically either asymptomatic or presents with non-specific symptoms. Pancreatic ductal adenocarcinoma thus remains a highly fatal disease. Today, surgical resection (removal of the pancreas) is the only potentially curative modality of treatment available. Detecting pancreatic cancer lesions early enough to perform surgery is, however, beset with difficulties. Nevertheless, the timeline of progression from low-grade precursor lesions to invasive cancer does offer a window of opportunity to detect the disease earlier than is currently possible. By providing physicians with actionable information early enough for the cancer to be removed surgically, the overall 5-year pancreatic ductal adenocarcinoma survival rate could increase from 11% to over 50%. In this chapter, we describe the development and clinical implementation of a proteomic, multi-biomarker blood test for the early detection of pancreatic ductal adenocarcinoma.
– Name: URL
  Label: Access URL
  Group: URL
  Data: <link linkTarget="URL" linkTerm="https://doi.org/10.36255/exon-publications-gastrointestinal-cancers-biomarkers-pancreatic-cancer" linkWindow="_blank">https://doi.org/10.36255/exon-publications-gastrointestinal-cancers-biomarkers-pancreatic-cancer</link>
PLink https://erproxy.cvtisr.sk/sfx/access?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsswe&AN=edsswe.oai.portal.research.lu.se.publications.6b0a57a7.eb00.45a9.ab59.717692b71cc8
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.36255/exon-publications-gastrointestinal-cancers-biomarkers-pancreatic-cancer
    Languages:
      – Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 16
        StartPage: 85
    Subjects:
      – SubjectFull: Medical and Health Sciences
        Type: general
      – SubjectFull: Clinical Medicine
        Type: general
      – SubjectFull: Cancer and Oncology
        Type: general
      – SubjectFull: Medicin och hälsovetenskap
        Type: general
      – SubjectFull: Klinisk medicin
        Type: general
      – SubjectFull: Cancer och onkologi
        Type: general
    Titles:
      – TitleFull: Biomarkers for the Early Detection of Pancreatic Ductal Adenocarcinoma
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Borrebaeck, Carl A.K.
      – PersonEntity:
          Name:
            NameFull: Mellby, Linda D.
      – PersonEntity:
          Name:
            NameFull: King, Thomas C.
      – PersonEntity:
          Name:
            NameFull: Lund University, Faculty of Engineering, LTH, Departments at LTH, Department of Immunotechnology, Lunds universitet, Lunds Tekniska Högskola, Institutioner vid LTH, Institutionen för immunteknologi, Originator
      – PersonEntity:
          Name:
            NameFull: Lund University, Faculty of Engineering, LTH, Other operations, LTH, Create Health, Lunds universitet, Lunds Tekniska Högskola, Annan verksamhet, LTH, Create Health, Originator
      – PersonEntity:
          Name:
            NameFull: Lund University, Profile areas and other strong research environments, Other Strong Research Environments, LUCC: Lund University Cancer Centre, Lunds universitet, Profilområden och andra starka forskningsmiljöer, Övriga starka forskningsmiljöer, LUCC: Lunds universitets cancercentrum, Originator
      – PersonEntity:
          Name:
            NameFull: Lund University, Faculty of Engineering, LTH, LTH Profile areas, LTH Profile Area: Engineering Health, Lunds universitet, Lunds Tekniska Högskola, LTH profilområden, LTH profilområde: Teknik för hälsa, Originator
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-locals
              Value: SWEPUB_FREE
            – Type: issn-locals
              Value: LU_SWEPUB
          Titles:
            – TitleFull: Gastrointestinal Cancers
              Type: main
ResultId 1